PG-102 (Progen Pharmaceuticals)

N/A

Report date: 2026/04/15 20:02:38

Base Information

Drug NamePG-102 (Progen Pharmaceuticals)
Drug Alias NameMG-12MG12RT-114PG-102
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsGlucagon-like peptide 2 receptor agonists
TargetsGlucagon-like peptide 1 receptorGlucagon-like peptide 2 receptor
Therapy Area/IndicationsOverweightObesityDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaSouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesProGen Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSL Metagen IncProGen Co LtdRani Therapeutics Llc
Inactive CompaniesN/A
Active IndicationsOverweightObesityDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A